Coronavirus: Regeneron’s antiviral cocktail reduces viral load and need for medical care, trial shows
- Patients on therapy, which US President Donald Trump also received, were 57 per cent less likely to need medical care within month of treatment
- Cocktail appears to be most potent for those at higher risk, including older patients and those with other medical conditions
Regeneron Pharmaceuticals said data from a late-stage clinical trial suggest that its antibody cocktail therapy for Covid-19 significantly reduces virus levels and the need for further medical care.
Patients getting the therapy were 57 per cent less likely to need medical care within a month of treatment, with 2.8 per cent of those given the antibody and 6.5 per cent of those on placebo seeing a health care worker within 29 days.
The Tarrytown, New York-based company has shared the results with US regulators who are currently evaluated the antibody cocktail for an emergency use authorisation for high risk patients with mild-to-moderate Covid-19. Regeneron’s therapy was given to President Donald Trump earlier this month after he tested positive for the coronavirus.
Shares of Regeneron rose 3 per cent in after-hours trading in New York on Wednesday.
04:42
Trump returns to the White House after only three days in hospital for Covid-19 treatment
“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load,” said Chief Scientific Officer George Yancopoloulos.
Since the therapy had similar benefit at the high and low doses, Regeneron is considering a change to the dosing it is using in other outpatient studies that are under way. The change to a lower dose could help extend the limited available supply of the medication.